TITAN Solidifies Place for Apalutamide in Metastatic CSPC

MEDSCAPE

PUBLISHED: 06 JUNE 2019

New data show efficacy for the next-generation androgen receptor inhibitor apalutamide (Erleada, Janssen) in the treatment of metastatic hormone-sensitive prostate cancer, which would be a new indication for the drug.

TITAN Solidifies Place for Apalutamide in Metastatic CSPC

Published

June 6, 2019

Categories